WikiTrademarks - Search, analyse, and monitor trademark applications.

Trademark: NUCLEAR-DELIVERED ANTIBODY-DRUG CONJUGATES

Put your brand on the blockchain and timestamp its proof of existence at wikitrademarks.io

Tweet this

Track updates on NUCLEAR-DELIVERED ANTIBODY-DRUG CONJUGATES

Mark Identification

Proof of use for NUCLEAR-DELIVERED ANTIBODY-DRUG CONJUGATES

We do not have any records of a proof of use for NUCLEAR-DELIVERED ANTIBODY-DRUG CONJUGATES at this moment.

Click here to add a proof of use for NUCLEAR-DELIVERED ANTIBODY-DRUG CONJUGATES

Possible trademark infringements of NUCLEAR-DELIVERED ANTIBODY-DRUG CONJUGATES

Basic Information about NUCLEAR-DELIVERED ANTIBODY-DRUG CONJUGATES

Serial Number
97296549
Filing Date
04 Mar 2022
Registration Number
7064074
Registration Date
23 May 2023
Mark Drawing Code
4

Classifications

Declare the trademark use of NUCLEAR-DELIVERED ANTIBODY-DRUG CONJUGATES on the blockchain with WikiTrademarks.io.

First use of NUCLEAR-DELIVERED ANTIBODY-DRUG CONJUGATES anywhere
NUCLEAR-DELIVERED ANTIBODY-DRUG CONJUGATES was first used on 10 Jan 2020 for the primary classification of goods and services, international, 042 (Computer, scientific & legal)
First use in commerce
There is no first use of this trademark in commerce detected yet.
Status Code
6
International Code
042
US Codes
100; 101

Who owns NUCLEAR-DELIVERED ANTIBODY-DRUG CONJUGATES?

1. Angiex, Inc. Cambridge MA

2. Angiex, Inc. Cambridge MA

Correspondent

Chelsea E. Carbone
WILSON SONSINI GOODRICH & ROSATI
650 PAGE MILL ROAD
PALO ALTO CA 94304-1050

Put your brand on the blockchain and timestamp its proof of existence at Wikitrademarks.io

Tweet this

Track updates on NUCLEAR-DELIVERED ANTIBODY-DRUG CONJUGATES